
    
      Approximately 50 centers worldwide will participate in the study. Additional centers outside
      the US may be considered, as necessary. The anticipated enrollment duration is 48-60 months.

      This study provides a mechanism for sites to refer subjects for potential enrollment to the
      Substrate Targeted Ablation Using the FlexAbilityâ„¢ Ablation Catheter System for the Reduction
      of Ventricular Tachycardia (STAR-VT) Investigational Device Exemption (IDE) study
      (ClinicalTrials.gov NCT02130765).

      Patients receiving ICD or CRT-D device implant (or have received it within 30 days) may be
      enrolled in the study.
    
  